Aptose Biosciences (TSE:APS) Lowered to “Hold” Rating by Alliance Global Partners

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) was downgraded by analysts at Alliance Global Partners from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Aptose Biosciences Stock Down 0.9%

Aptose Biosciences stock opened at C$2.29 on Monday. The company has a market capitalization of C$5.84 million, a P/E ratio of 3.32 and a beta of -0.05. Aptose Biosciences has a 1-year low of C$1.02 and a 1-year high of C$16.50. The firm’s fifty day simple moving average is C$1.81 and its 200-day simple moving average is C$1.88. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last posted its earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share for the quarter. Sell-side analysts forecast that Aptose Biosciences will post -0.59 earnings per share for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.